Immunovant, Inc. (IMVT)Healthcare | Biotechnology | Durham, United States | NasdaqGS
41.20 USD
-2.62
(-5.979%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 40.58 -0.62 (-0.620%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:15 a.m. EDT
The immediate outlook is defined by a stark divergence between the company's recent price recovery and its deteriorating fundamental reality. While the stock has rallied nearly 50% over the last six months, driven by positive trial data and a recent earnings miss that failed to drag prices down, the underlying business remains in a severe cash burn phase with negative free cash flow and no dividend support. The market appears to be pricing in a binary event: either the drug pipeline delivers a blockbuster approval that justifies the current valuation, or the cash reserves deplete, forcing a dilutive capital raise or bankruptcy. The heavy put positioning suggests that while some investors are betting on the catalyst, the majority are hedging against a failure of that thesis. Given the negative earnings, high book value discount, and lack of revenue, this is a high-risk speculative vehicle suitable only for investors willing to tolerate total loss potential in exchange for asymmetric upside on a single clinical success. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.026427 |
| MSTL | 0.049338 |
| AutoARIMA | 0.055736 |
| AutoETS | 0.058528 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.538 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 8,509,970,944 |
| Forward P/E | -14.98 |
| Beta | 0.81 |
| Website | https://immunovant.com |
As of Aug. 22, 2026, 5:15 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 20-35) across multiple expirations, particularly in the December and January 2027 windows where put volume dwarfs call volume. Conversely, call activity is concentrated near the money and slightly out-of-the-money, with significant open interest at strikes 45 and 50, suggesting a speculative bid for a rebound to current levels rather than a breakout to new highs. Implied volatility is elevated across the board, reflecting uncertainty surrounding the company's clinical trial results and earnings performance.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9077637 |
| Address1 | 1,000 Park Forty Plaza |
| Address2 | Suite 210 |
| All Time High | 53.75 |
| All Time Low | 3.145 |
| Ask | 52.71 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,081,480 |
| Average Daily Volume3 Month | 1,287,369 |
| Average Volume | 1,287,369 |
| Average Volume10Days | 1,081,480 |
| Beta | 0.81 |
| Bid | 30.83 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 3.565 |
| City | Durham |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 41.2 |
| Current Ratio | 7.269 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 43.375 |
| Day Low | 41.085 |
| Display Name | Immunovant |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -565,606,976 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.635 |
| Enterprise Value | 7,712,172,544 |
| Eps Current Year | -2.8398 |
| Eps Forward | -2.7502 |
| Eps Trailing Twelve Months | -2.81 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 40.0904 |
| Fifty Day Average Change | 1.1096001 |
| Fifty Day Average Change Percent | 0.02767745 |
| Fifty Two Week Change Percent | 190.77637 |
| Fifty Two Week High | 45.42 |
| Fifty Two Week High Change | -4.2199974 |
| Fifty Two Week High Change Percent | -0.09291056 |
| Fifty Two Week Low | 14.58 |
| Fifty Two Week Low Change | 26.62 |
| Fifty Two Week Low Change Percent | 1.8257889 |
| Fifty Two Week Range | 14.58 - 45.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,123,800,000 |
| Float Shares | 91,587,525 |
| Forward Eps | -2.7502 |
| Forward P E | -14.980729 |
| Free Cashflow | -238,703,632 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 315 |
| Fullday Change | -2.62 |
| Fullday Change Percent | -5.979 |
| Fullday Price | 40.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.56019 |
| Held Percent Institutions | 0.53976 |
| Implied Shares Outstanding | 206,552,682 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. |
| Long Name | Immunovant, Inc. |
| Market | us_market |
| Market Cap | 8,509,970,944 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_592774643 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -538,217,024 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 9,055,269,578 |
| Number Of Analyst Opinions | 16 |
| Open | 43.27 |
| Operating Cashflow | -414,304,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 917 410 3120 |
| Post Market Change | -0.61999893 |
| Post Market Change Percent | -1.5048517 |
| Post Market Price | 40.58 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 43.82 |
| Price Eps Current Year | -14.508065 |
| Price Hint | 2 |
| Price To Book | 11.556802 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.819 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.625 |
| Region | US |
| Regular Market Change | -2.62 |
| Regular Market Change Percent | -5.979 |
| Regular Market Day High | 43.375 |
| Regular Market Day Low | 41.085 |
| Regular Market Day Range | 41.085 - 43.375 |
| Regular Market Open | 43.27 |
| Regular Market Previous Close | 43.82 |
| Regular Market Price | 41.2 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,082,320 |
| Return On Assets | -0.46733 |
| Return On Equity | -0.80096 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 206,552,682 |
| Shares Percent Shares Out | 0.082200006 |
| Shares Short | 16,981,939 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 17,758,956 |
| Short Name | Immunovant, Inc. |
| Short Percent Of Float | 0.18280001 |
| Short Ratio | 17.07 |
| Source Interval | 15 |
| State | NC |
| Symbol | IMVT |
| Target High Price | 66.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 48.875 |
| Target Median Price | 48.5 |
| Total Cash | 797,798,016 |
| Total Cash Per Share | 3.862 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.063326 |
| Two Hundred Day Average Change | 11.136675 |
| Two Hundred Day Average Change Percent | 0.37044054 |
| Type Disp | Equity |
| Volume | 1,082,320 |
| Website | https://immunovant.com |
| Zip | 27,713 |